Working… Menu

Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03586024
Recruitment Status : Withdrawn (poor accrual)
First Posted : July 13, 2018
Last Update Posted : May 7, 2021
Information provided by (Responsible Party):
Abramson Cancer Center of the University of Pennsylvania

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Actual Primary Completion Date : August 19, 2020
Actual Study Completion Date : August 19, 2020